Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Next Previous
X
Search
Trial Profile

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms BEGIN:ADD TO GLP-1 Study
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 18 Sep 2014 Primary endpoint has been met (change from baseline in glycosylated haemoglobin) according to results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 18 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 09 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top